Allurion Combines Capsule with Low-Dose Tirzepatide to Optimize Weight Loss and Muscle Mass

Allurion Technologies has announced initial results of combining their weight loss program with low-dose tirzepatide therapy. 76 patients treated with the Allurion Smart Capsule and low-dose tirzepatide achieved an average total body weight loss of 23% and a 14% increase in lean body mass over 12 months. No patients discontinued early, and all remained adherent to tirzepatide for the study duration. The combination approach aims to optimize muscle mass and GLP-1 adherence.